Abdul Mannan: A Red Eye, a Blood Clot, and Ibrutinib – The Clinical Tightrope
Abdul Mannan, Consultant Hematologist at Betsi Cadwaladr University Health Board, shared a post on LinkedIn:
“A red eye. A blood clot. And ibrutinib. This is the clinical tightrope.
My SLL patient was on ibrutinib 420 mg for her disease and therapeutic anticoagulation for a massive PE.
Then her eye turned red. Spontaneous subconjunctival haemorrhage. No major bleeding anywhere.
The question every haematologist dreads: Do I stop something? And if so, what?
Here is the answer the evidence gives us.
The red eye is Grade 1. It is minor. It is expected. Ibrutinib knocks out BTK and Tec kinase together, crippling platelet adhesion via GPVI/collagen and GPIb/vWF pathways.
The result is platelet dysfunction, not thrombocytopenia. Mucocutaneous bleeding happens in up to 67% of patients on ibrutinib. A subconjunctival bleed is part of that story.
But stacking anticoagulation on top? That is where the real risk lives.
What the numbers tell us (Roccograndi et al., Leukemia & Lymphoma 2023, n=64 CLL/SLL patients):
- Apixaban used with ibrutinib: 6% major bleeding
- Rivaroxaban used with ibrutinib: 18% major bleeding
- Enoxaparin used with ibrutinib: 0% (small numbers, but reassuring)
Warfarin: contraindicated, full stop
Ibrutinib combined with DOAC and clopidogrel:
one fatal intracranial haemorrhage
Wang et al. meta-analysis (Frontiers in Pharmacology 2020, 11 RCTs, 4,288 patients) showed ibrutinib triples overall bleeding risk in CLL patients.
So what did I do?
Continued ibrutinib. Continued anticoagulation. The PE does not forgive you for stopping. Checked she was on apixaban not rivaroxaban. Checked renal function. Removed every antiplatelet from her list. Educated her on CNS and GI red flag symptoms.
The infographic below tells the whole story in one page. Save it. Share it with your trainees.
- Bleed concern: LOW.
- Overall vigilance: HIGH.
Have you faced this combination in practice? What anticoagulant did you go with?”
Other posts featuring Abdul Mannan on Hemostasis Today.
-
Nov 4, 2026, 18:57Connecting Haemophilia Centres, Certifying Treaters, and Improving National Data in Romania – EHC
-
Nov 4, 2026, 18:45Smitirupa Mishra: A Practical Guide to Coagulation Pathway Assessment and Laboratory Interpretation
-
Nov 4, 2026, 15:59Alessandra Bosch: A Successful Patient Day for the Bleeding Disorders Community in Zürich
-
Nov 4, 2026, 15:47Wolfgang Miesbach: Targeting Hepatic Endothelial Cells for Lentiviral Gene Therapy in Haemophilia A
-
Nov 4, 2026, 15:20Augustina Isioma Ikusemoro: Before You Transfuse, Think PBM
-
Nov 4, 2026, 14:23Advancing Hemophilia Care Through Global Research – WFH
-
Nov 4, 2026, 14:12Jean-Jacques Kiladjian: From JAK Inhibitor-Associated Skin Cancers to Laboratory Discovery
-
Nov 4, 2026, 13:59Rita Li: ASH 2026 Abstract Achievement Award for Gut Microbiome Research
-
Nov 4, 2026, 13:38Omid Seidizadeh: Improving Access to von Willebrand Disease Diagnosis and Treatment Across Europe